Discontinuation of maintenance selective serotonin reuptake inhibitor monotherapy after 5 years of stable response: A naturalistic study

Journal of Clinical Psychiatry

Volumn 69, Issue 11, 2008, Pages 1811-1817

  Pundiak, Tara M ^a,d   Case, Brady G ^a,b,c   Peselow, Eric D ^a   Mulcare, Loretta ^a  

^a Freedom from Fear   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d FPO ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; PAROXETINE; SERTRALINE;

ADULT; ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NATURALISTIC INQUIRY; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; TREATMENT WITHDRAWAL;

EID: 57349120983     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n1117     Document Type: Article

References (43)

1. Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005;62: 1097-1106
2. Kessler RC, Zhao S, Blazer DG, et al. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. J Affect Disord 1997;45:19-30
3. Cuijpers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. J Affect Disord 2002;72:227-236
4. von Ammon Cavanaugh S, Furlanetto LM, Creech SD, et al. Medical illness, past depression, and present depression: a predictive triad for in-hospital mortality. Am J Psychiatry 2001;158:43-48
5. Wulsin LR, Vaillant GE, Wells VE. A systematic review of the mortality of depression. Psychosom Med 1999;61:6-17
6. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-418
7. Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000;22:153-162
8. Lane R, McDonald G. Reducing the economic burden of depression. Int Clin Psychopharmacol 1994;9:229-243
9. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999;156:1000-1006
10. US Food and Drug Administration (FDA) Center for Drug Evaluation and Research. Drugs @ FDA: FDA Approved Drug Products. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction= Search.DrugDetails. Accessed Feb 21, 2007
11. Tardieu S, Bottero A, Blin P, et al. Roles and practices of general practitioners and psychiatrists in management of depression in the community. BMC Fam Pract 2006 Jan;7:5
12. Wong DT, Perry KW, Bymaster FP. Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov 2005;4:764-774
13. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000 Apr;157(suppl 4):1-45
14. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217-222
15. Gilaberte I, Montejo AL, de la Gandara J, et al, Fluoxetine Long-Term Study Group. Fluoxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol 2001;21:417-424
16. Hochstrasser B, Isaksen PM, Koponen H, et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 2001;178:304-310
17. Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998;280:1665-1672
18. Klysner R, Bent-Hansen J, Hansen HL, et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002;181:29-35
19. Lepine JP, Caillard V, Bisserbe JC, et al. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 2004;161:836-842
20. McGrath PJ, Stewart JW, Petkova E, et al. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. J Clin Psychiatry 2000;61:518-524
21. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry Suppl 1988 Sep;(3):69-76
22. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189-195
23. Montgomery SA, Rasmussen JG. Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1992 Jun;6(suppl 5):71-73
24. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65:44-49
25. Reynolds CF III, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N Engl J Med 2006;354:1130-1138
26. Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995 Mar;10(suppl 1):29-35
27. Terra JL, Montgomery SA. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998;13:55-62
28. Wilson KC, Mottram PG, Ashworth L, et al. Older community residents with depression: long-term treatment with sertraline: randomised, double-blind, placebo-controlled study. Br J Psychiatry 2003;182: 492-497
29. Zimmerman M, Chelminski I. Clinician recognition of anxiety disorders in depressed outpatients. J Psychiatr Res 2003;37:325-333
30. Corruble E, Ginestet D, Guelfi JD. Comorbidity of personality disorders and unipolar major depression: a review. J Affect Disord 1996;37: 157-170
31. Iosifescu DV, Bankier B, Fava M. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Curr Psychiatry Rep 2004;6:193-201
32. Akiskal HS. Mood disorders. In: Sadock BJ, Sadock VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, vol. 1. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:1353
33. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998;55:694-700
34. Kupfer DJ, Frank E, Perel JM, et al. Five-Year Outcome for Maintenance Therapies in Recurrent Depression. Arch Gen Psychiatry 1992;49: 769-773
35. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
36. Williams JB, Gibbon M, First MB, et al. The Structured Clinical Interview for DSM-III-R (SCID), II: multisite test-retest reliability. Arch Gen Psychiatry 1992 Aug;49(8):630-636
37. Asberg M, Montgomery SA, Perris C, et al. A comprehensive psychopathological rating scale. Acta Psychiatr Scand Suppl 1978;(271):5-27
38. Kornstein SG, Bose A, Li D, et al. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2006;67:1767-1775
39. Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000 Feb;157(2):229-233
40. Bockting CL, Spinhoven P, Koeter MW, et al, Depression Evaluation Longitudinal Therapy Assessment Study Group. Prediction of recurrence in recurrent depression and the influence of consecutive episodes on vulnerability for depression: a 2-year prospective study. Clin Psychiatry 2006;67:747-755
41. Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry 2005;66(suppl 8):22-29
42. Kool S, Schoevers R, de Maat S, et al. Efficacy of pharmacotherapy in depressed patients with and without personality disorders: a systematic review and meta-analysis. J Affect Disord 2005;88:269-278
43. Black K, Shea C, Dursun S, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 2000;25:255-261